CAR-T and Dendritic Cell Therapies Show Promise in Tackling Glioblastoma

Published on Spencer Knight via LinkedIn

Glioblastoma remains one of the deadliest brain cancers with limited treatment options. Two new cell therapy strategies are now making headway:

• Gilead/Kite’s dual-target CAR-T therapy (EGFR + IL13Rα2) shrank tumors in 62% of patients with recurrent glioblastoma. Some even saw tumor stability lasting over a year.

• Diakonos Oncology is advancing a dendritic cell therapy called dubocelencel, designed to stimulate a TH1 immune response without toxic IL-2 or modified immune cells. Backed by a $20M raise, they’ve entered Phase II with Fast Track and Orphan Drug status.

Spencer Knight highlights this momentum in neuro-oncology as a long-awaited step toward better options for one of medicine’s most difficult challenges.

Read the full article via Reuters:

👉 Gilead’s CAR-T cell therapy shows promise in deadly brain cancer

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.